Literature DB >> 20875358

Pulmonary hypertension in congenital shunts.

Maurice Beghetti1, Cecile Tissot.   

Abstract

Pulmonary arterial hypertension frequently arises in patients with congenital heart disease. The vast majority present with congenital cardiac shunts. Initially these may manifest as left-to-right (i.e. systemic-to-pulmonary) shunts. The natural history of disease progression involves vascular remodeling and dysfunction that lead to increased pulmonary vascular resistance and, finally, to the development of Eisenmenger's syndrome, which is the most advanced form. The anatomical, pathological and structural abnormalities occurring in the pulmonary circulation of these patients are, to some extent, similar to those observed in other forms of pulmonary arterial hypertension. This understanding has recently led to significant changes in the management of Eisenmenger's syndrome, with the introduction of treatment specifically targeting pulmonary vascular disease. Early closure of the cardiac shunt remains the best way of preventing pulmonary vascular lesions. However, it is still not clear which preoperative parameters predict safe and successful repair, though hemodynamic evaluation is still routinely used for assessment. Postoperative pulmonary hypertension, both in the immediate period after surgical repair and during long-term follow-up, remains a real therapeutic challenge. The clinical situation of a single ventricle with Fontan circulation also presents difficulties when pulmonary vascular lesions are present. This article reviews pulmonary hypertension associated with congenital shunts and discusses a number of the specific problems encountered.

Entities:  

Mesh:

Year:  2010        PMID: 20875358     DOI: 10.1016/s1885-5857(10)70232-2

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  5 in total

1.  Serum Pentraxin 3 and hs-CRP Levels in Children with Severe Pulmonary Hypertension.

Authors:  Cemşit Karakurt; Osman Başpınar; Fazlı Serkan Çelik; Çağatay Taşkapan; Aydın Derya Şahin; Saim Yoloğlu
Journal:  Balkan Med J       Date:  2014-09-01       Impact factor: 2.021

2.  Asymmetric Dimethyl-L-Arginine is a Biomarker for Disease Stage and Follow-Up of Pulmonary Hypertension Associated with Congenital Heart Disease.

Authors:  Zhen-fei Fang; Yi-yuan Huang; Liang Tang; Xin-qun Hu; Xiang-qian Shen; Jian-jun Tang; Sheng-hua Zhou
Journal:  Pediatr Cardiol       Date:  2015-03-04       Impact factor: 1.655

3.  Better Outcomes in Pulmonary Arterial Hypertension After Repair of Congenital Heart Disease, Compared With Idiopathic Pulmonary Arterial Hypertension.

Authors:  Zhuoyuan Xu; Michael A Gatzoulis; Konstantinos Dimopoulos; Qiangqiang Li; Chen Zhang; Bradley B Keller; Hong Gu
Journal:  CJC Open       Date:  2021-02-17

4.  Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts.

Authors:  Chodchanok Vijarnsorn; Kritvikrom Durongpisitkul; Paweena Chungsomprasong; Densiri Bositthipichet; Salisa Ketsara; Yuttapon Titaram; Prakul Chanthong; Supaluck Kanjanauthai; Jarupim Soongswang
Journal:  PLoS One       Date:  2018-04-17       Impact factor: 3.240

5.  Vessel network extraction and analysis of mouse pulmonary vasculature via X-ray micro-computed tomographic imaging.

Authors:  Eric A Chadwick; Takaya Suzuki; Michael G George; David A Romero; Cristina Amon; Thomas K Waddell; Golnaz Karoubi; Aimy Bazylak
Journal:  PLoS Comput Biol       Date:  2021-04-20       Impact factor: 4.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.